Breast Cancer
Conditions
Brief summary
This study examines the impact of an additional tumour test called the 21 gene Recurrence Score (OncotypeDx®), a commercially available test on a Medical Oncologist's decision to recommend chemotherapy.
Detailed description
After a breast cancer and any lymph glands have been surgically removed, further (adjuvant) treatment is generally given to reduce the risk of cancer recurrence. For patients with estrogen receptor (ER) positive breast cancer, this treatment has traditionally been chemotherapy and hormone therapy. However, it is increasingly recognised that tumours which are ER positive and negative for the human epidermal growth factor receptor 2 (HER2), are relatively resistant to chemotherapy. It is likely that many more people are exposed to the risks for chemotherapy than ever benefit from it. In order to select patients who will get more benefit from chemotherapy and to spare those who get very little benefit from side effects, risk assessment tools are being developed. The 21 Gene Recurrence Score is a test that examines the tumour genes to estimate the risk of the tumour relapsing and possible chemotherapy benefits. Currently, the 21 Gene Recurrence Score (OncotypeDx®) is used In Ireland for patients with no cancer in their lymph nodes. For these patients it can help in deciding who should get chemotherapy. Patients with low scores can sometimes avoid chemotherapy. In some countries, this test is offered to almost all patients with ER positive breast cancer, irrespective of whether the cancer has spread to lymph nodes or not. However, in Ireland this test is not standardly available for patients who have breast cancer involving lymph nodes.
Interventions
None listed
Sponsors
Cancer Trials Ireland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria (All Patients) 1. Age 18 years of age or older 2. ER Positive Tumours (≥1% positive cells or Allred score ≥ 2 (Appendix 1)) 3. Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer (0-1 by IHC or FISH \<2.0) 4. No evidence of metastatic disease on CT, bone scan or other imaging 5. Fit for consideration of chemotherapy as determined by the Investigator 6. Adequate performance status (Eastern Cooperative Oncology Group (ECOG) 0 or 1 (Appendix 2)) Inclusion Criteria - Cohort 1 (Postoperative Patients): N= 75 1. Adequate surgical excision of breast tumour (mastectomy or lumpectomy) and lymph nodes (sentinel lymph biopsy or axillary dissection) 2. Any tumour size (T stage (Appendix 3)) 3. Involvement of 1-3 lymph nodes (N1, including micrometastases) Inclusion Criteria - Cohort 2 (Preoperative Patients): N= 75 1. Candidates for preoperative therapy for early breast cancer 2. T2-T4 tumours 3. Involvement of at least one lymph node, (including micrometastases) on biopsy 4. Adequate tissue from core biopsy for 21 gene RS testing (approximate minimum 5mm)
Exclusion criteria
(All patients): 1. ER negative tumour (Allred score 0-1) 2. HER2 positive tumours as defined by IHC 3+ or FISH ≥ 2.0 3. Node negative disease, including those with Isolated tumour cells only (node negative i+/i-) 4. Known metastatic breast cancer 5. Performance status ≥ 2 6. Patients not considered by their treating physician to be fit to undergo chemotherapy. 7. Men with breast cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Chemotherapy | 3 years | The percentage reduction in the number of patients for whom chemotherapy is recommended following resection of their primary breast cancer and testing with the 21 gene RS (cohort 1; n=75) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of gene RS | 3 years | Examine the impact of the 21 gene RS on chemotherapy recommendations in operable breast cancer in the postoperative and preoperative setting (cohorts 1 and 2; n=150) using questionnaires completed by Medical Oncologists. |
| Complete Response | 3 years | Investigate the correlation between the 21 gene RS and pathological complete response from preoperative therapy in operable breast cancer (cohort 2; n=75). |
| Radiological Response Rate | 3 years | Determine whether the 21 gene RS correlates with clinical, radiological response rate and the MD Anderson residual cancer burden score following preoperative therapy (cohort 2; n=75). |
| Economic Impact | 3 years | Determine the economic impact of the 21 gene RS testing on ER positive, node positive breast cancer patients (cohorts 1 and 2; n=150) using a simple budget impact model |
Countries
Ireland
Contacts
PRINCIPAL_INVESTIGATORDr Patrick Morris
Beaumont Hospital
Outcome results
None listed